medigraphic.com
Colegio de Medicina Interna de México.

2010, Number 5

<< Back Next >>

Med Int Mex 2010; 26 (5)

reatment of premature ejaculation. Viewpoint of the internist

Aldrete VJ, Janeiro SMR, Aldrete ASM

Language: Spanish
References: 21
Page: 485-491
PDF size: 210.78 Kb.


ABSTRACT

Premature ejaculation (PE) is the most common male sexual disorder, with prevalence rates ranging from 24 to 31%. The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) defines PE as a persistent and recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration, causing a marked distress. Nonetheless, the timing of intravaginal ejaculatory latency time (IELT) has been suggested for its definition. At the moment of making the diagnosis it is important to elaborate a complete medical history and physical examination in order to rule out systemic diseases (neurological, endocrine, cardiovascular, etc). Nowadays, we have and ample range of pharmacological therapy, being the selective serotonin reuptake inhibitors (SSRIs) the preferred treatment due to their significant effect in the prolongation of the IELT and their few adverse reactions. In a recent clinical trial conducted in Mexico city, paroxetine at daily doses of 15 and 20 mg, was found to be effective and safe for the treatment of PE; observing significant statistical differences in the IELT and PE index compared with placebo. These esults should be use as an incentive to continue the conduction of clinical trials in Mexico and solve the questions that still remain.


REFERENCES

  1. Laumann EO, Nicolosi A, Glasser DB, Paik A, et al. Sexual problems among women and men aged 40-80: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005;17:39-57.

  2. Palmer NR, Stuckey BG. Premature ejaculation: a clinical update. Med J Aust 2008;188:662-666.

  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington: APA, 2000.

  4. Guideline on the pharmacologic management of premature ejaculation (reviewed in 2008). American Urological Association (http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/pme/pme_2004.pdf).

  5. International Society for Sexual Medicine. ISSM definition of premature ejaculation (http://www.issm.info/prod/system/main/ index.asp [accessed Mar 2008]).

  6. Patrick DL, Althof SE, Pryor JL, Rosen R, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med 2005;2:358-367.

  7. Sadovsky R, Althof S. Men’s sexual issues. Clin Fam Pract 2004;6:863-915.

  8. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-544.

  9. Rosen RC, Porst H, Montorsi F. The Premature EjaculationPrevalence and Attitudes (PEPA) survey: a multi-nationalsurvey. J Sex Med 2004;1(Suppl 1):57.

  10. Sánchez BC, Carreño MJ, Martínez S, Gómez ME. Disfunciones sexuales femeninas y masculinas: comparación de género en una muestra de la Ciudad de México. Rev Sal Ment 2005;28:74-80.

  11. Payne RE, Sadovsky R. Identifying and treating premature ejaculation: importance of the sexual history. Cleve Clin J Med 2007;74(Suppl 3):S47-S53.

  12. Kandeel FR, Koussa VK, Swerdloff RS. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocrine Reviews 2001;22:342-388.

  13. Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a doublebind, placebo controlled study. J Urol 1998;159:425-427.

  14. Berkovitch M, Keresteci AG, Koren G. Efficacy of prilocainelidocaine cream in the treatment of premature ejaculation. J Urol 1995;154:1360-1361.

  15. McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int 2006;98:259-272.

  16. Pryor JL, Althof SE, Steidle C, Rosen RC, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006;368:929-937.

  17. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004;16:369-381.

  18. Rubio-Aurioles E, Jaspersen-Gastelum J, Berber A, López LM y col. Hemihidrato del clorhidrato de paroxetina para eyaculación precoz en la población mexicana: un ensayo prospectivo, multicéntrico y paralelo, controlado con placebo, aleatorizado y doble ciego para estudiar la eficacia y seguridad de dosis diarias de 15 y 20 mg de hemihidrato del clorhidrato de paroxetina en el tratamiento de la eyaculación precoz de diferentes tipos. Rev Mex Urología 2010;70(Supl 1):1-17.

  19. Waldinger MD. Premature ejaculation: definition and drug treatment. Drugs 2007;67:547-568.

  20. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. The majority of men with life long premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med 2007;4:1028-1037.

  21. Waldinger MD. Premature ejaculation: state of the art. Urol Clin North Am 2007;34(4):591-599.




2020     |     www.medigraphic.com